Theravance Biopharma Announces New Employment Inducement

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Theravance Biopharma Announces New Employment Inducement Awards

DUBLIN, IRELAND--(Marketwired - Feb 2, 2016) - Theravance Biopharma, Inc. ( NASDAQ : TBPH ) ("Theravance Biopharma" or the "Company") announced today that stock options to purchase an aggregate of 63,850 of the Company's ordinary shares were granted to twelve new non-executive officer employees on February 1, 2016. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4) under the Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan (the "Inducement Plan"), which the Board of Directors of Theravance Biopharma adopted in October 2014 to facilitate the granting of equity awards to new employees. Each option has an exercise price per share equal to $16.01, which was the closing price of one Theravance Biopharma ordinary share on the Nasdaq Global Market on the date of grant. The options vest over four years, with 25% of the option shares vesting on the first anniversary of the date of grant and the remaining 75% of the option shares vesting in monthly installments over the three years thereafter. The options have a ten year term, and are subject to the terms and conditions of the Inducement Plan and applicable stock option agreement.

About Theravance Biopharma

The mission of Theravance Biopharma ( NASDAQ : TBPH ) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.

Our pipeline of internally discovered product candidates includes potential best-in-class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIV ® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revenfenacin (TD-4208) is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily, oral treatment for opioid-induced constipation (OIC). Our earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates ("GSK") pursuant to its agreements with Innoviva, Inc. (formerly Theravance, Inc.) relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the "Closed Triple").

With our successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, we believe that we are well positioned to create value for our shareholders and make a difference in the lives of patients.

For more information, please visit www.theravance.com .

THERAVANCE ® , the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE ® and VIBATIV ® are registered trademarks of the Theravance Biopharma group of companies.

Contact Information: Renee Gala Chief Financial Officer 650-808-4045 investor.relations@theravance.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carbonization Furnaces Turn Waste Rules Into Demand

Updated Category News Views 84

Smoke has become an expensive habit for farmers, mills, and municipalities. That is the real commercial backdrop for carbonization furnaces, not some glossy green-tech slogan. MarketsandMarkets estimates this small global equipment market at $310 million in 2026 and projects $510 million by 2031, a 10.2% compound annual growth rate. For a capital-equipment niche, that is...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 77

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading
Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 59

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 56

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 60

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 146

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 140

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 101

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 104

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Elanco’s $600 Million Buyback Signals a New Chapter

Updated Category News Views 84

Debt coming down and cash coming in finally gave Elanco room to breathe. On Nov. 19, 2026, the animal-health company authorized its first-ever share repurchase program, allowing up to $600 million of common-stock purchases. For NYSE: ELAN, this is more than a flashy capital-return headline. It marks a shift from the ugly but necessary job of balance-sheet repair toward a...

Continue Reading

Top 5 Most Recently Viewed Articles

Bret Baier's Exclusive Interview with Trump on FOX Super Bowl Show

Updated Category News Views 296

Bret Baier's Exclusive Interview with President Donald Trump In a highly anticipated television event, Bret Baier, the chief political anchor for FOX News Channel (FNC), will engage in a significant one-on-one interview with President Donald Trump during the FOX Super Bowl LIX pregame show. This exclusive interview will air in the 3 PM/ET hour and is set to be a revealing...

Continue Reading
3D Systems Corporation Lawsuit Notification: What Investors Should Know

Updated Category News Views 169

3D Systems Corporation Lawsuit Overview The Gross Law Firm has issued a notice regarding an important class action lawsuit that involves shareholders of 3D Systems Corporation (NASDAQ: DDD). This legal action arises from allegations concerning misleading statements made by the company during a specific class period that could affect investors significantly. Understanding...

Continue Reading
5W PR Takes Charge of Marketing Strategies for Bedsure Pet

Updated Category News Views 191

5W PR Appointed as Agency of Record for Bedsure Pet Bedsure Pet, a leader in pet essentials, has recently welcomed 5W PR as their Agency of Record. This collaboration aims to elevate the brand's visibility and credibility in the competitive pet products market. About Bedsure Pet Products Bedsure Pet is celebrated for offering a wide range of high-quality pet products,...

Continue Reading
Itafos Enhances Financial Stability by Selling St George Shares

Updated Category News Views 155

Itafos Strengthens Financial Position Through Share Monetization HOUSTON, Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) has made headlines with its recent strategic move to partially monetize its equity interest in St George Mining Limited. This transaction, framed within the context of a larger corporate strategy, was initially announced following the sale of the Araxá...

Continue Reading
Hawkeye Invest AS Expands Stake in PCI Biotech Holding ASA

Updated Category News Views 343

Hawkeye Invest AS Enhances its Investment in PCI Biotech Holding ASA In a significant move, Hawkeye Invest AS, under the leadership of Øystein Barmen, has increased its stake in PCI Biotech Holding ASA by acquiring an additional 240,000 shares. This latest purchase has elevated their total ownership to 2,000,000 shares, representing a noteworthy 5.36% of the total shares...

Continue Reading